InvestorsHub Logo
Followers 5
Posts 71
Boards Moderated 0
Alias Born 12/15/2011

Re: None

Monday, 01/02/2012 8:30:16 PM

Monday, January 02, 2012 8:30:16 PM

Post# of 92948
This is only my second post since I recently joined this board. There is one thing a lot of people missed when you watch the presentation by Dr. Schwartz. At one point in the Q&A he states " These patients are heroes because they clearly knew going into this it was very unlikely they would get any improvement in their vision or function". He goes on to say they did it to advance science. I take this as these patients probably didn't get any improvement in their vision. I understand that is not the purpose of thIs phase of the trials but we are all hoping that they did as it would cause the stock to skyrocket. My take is that the cells did implant and there were no safety issues at all which is positive. The reason why the patients asked to have their other eye done was it was likely they injected their worst eye since they were legally blind and since the cells did implant, the patients would want their better eye injected now to possibly prevent it from getting worse. This is still positive but it will likely mean that we are going to need more patients that aren't as severe to prove you can either stop the process or delay it.
Again, we are all just guessing at this point what might be going on but once this does get out in the press, this is my guess as to what we are going to see. It is still a positive but not quite what most of us are hoping for. We would all love to see some improvement in vision in these 2 patients but that is not the impression I got once I saw his presentation.
I own a lot of stock in this company and will continue to hold it. I just hope very soon they will start the next patients so they can see either improvement in less severe patients or a halt in the worsening of vision.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.